60 DEGREES PHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 15, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

SXTP$0.55-8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Condensed Statements of Shareholders’ Equity

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY(UNAUDITED)

	For the Three Months Ended March 31, 2026
Series A Preferred Stock · Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders’ Equity Attributable to 60P · Noncontrolling Interest on Shareholders · Total Shareholders' Equity
Shares · Amount · Shares · Amount
Balance—December 31, 2025	76,480	$9,567,439	1,163,142	$116	$41,646,139	$(47,893,115)	$142,598	$3,463,177	$(83,761)	$3,379,416
Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)	-	-	1,473,708	148	3,369,604	-	-	3,369,752	-	3,369,752
Share rounding adjustment for 1:4 Reverse Stock Split	-	-	(62)	-	-	-	-	-	-	-
Share-based compensation expense	-	-	-	-	79,524	-	-	79,524	-	79,524
Net foreign translation gain	-	-	-	-	-		5,942	5,942	-	5,942
Net loss	-	-	-	-	-	(2,089,214)	-	(2,089,214)	(941)	(2,090,155)
Balance— March 31, 2026 (unaudited)	76,480	$9,567,439	2,636,788	$264	$45,095,267	$(49,982,329)	$148,540	$4,829,181	$(84,702)	$4,744,479

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

	For the Three Months Ended March 31, 2025
Series A Preferred Stock · Common Stock(1) · Additional Paid-In Capital(1) · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Shareholders’ Equity Attributable to 60P · Noncontrolling Interest on Shareholders · Total Shareholders' Equity
Shares · Amount · Shares · Amount
Balance—December 31, 2024	76,480	$9,567,439	141,749	$14	$34,860,633	$(40,527,957)	$135,471	$4,035,600	$(80,594)	$3,955,006
Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)	-	-	51,079	5	804,341	-	-	804,346	-	804,346
Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)	-	-	75,176	8	908,619	-	-	908,627	-	908,627
Issuance of common stock upon exercise of Pre-Funded Warrants	-	-	96,300	9	1,917	-	-	1,926	-	1,926
Issuance of shares for annual performance bonuses, net of shares withheld for taxes	-	-	3,953	-	103,544	-	-	103,544	-	103,544
Share-based compensation expense	-	-	-	-	142,645	-	-	142,645	-	142,645
Net foreign translation loss	-	-	-	-	-	-	(9,904)	(9,904)	-	(9,904)
Net loss	-	-	-	-	-	(1,876,549)	-	(1,876,549)	(752)	(1,877,301)
Share rounding adjustment for 1:5 Reverse Stock Split	-	-	(7)	-	-	-	-	-	-	-
Balance— March 31, 2025 (unaudited)	76,480	$9,567,439	368,250	$36	$36,821,699	$(42,404,506)	$125,567	$4,110,235	$(81,346)	$4,028,889

(1) Prior periods presented have been adjusted to reflect the 1:4 reverse stock split on January 20, 2026.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.